Bucharest

• Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended recruitment
  2023-503501-11-00 5 2023-02-09 Metastatic Non-small Cell Lung Cancer
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult … Ended recruitment
  2022-500861-29-00 5 2023-01-12 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study to Evaluate Investigational Therapies in Chronic Hepatitis D Virus Infection. Ended recruitment
  2024-512203-40-00 4 2022-11-24 Chronic Hepatitis D Virus (HDV) Infection
• The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended recruitment
  2024-510871-39-00 4 2022-11-21 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended recruitment
  2023-505579-53-00 5 2022-10-25 Diffuse large B-cell lymphoma (DLBCL)
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended recruitment
  2024-511068-10-00 5 2022-08-04 Sjögren’s Syndrome
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n … Ended recruitment
  2023-508559-37-00 5 2022-07-14 Lupus nephritis
• A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with … Ended recruitment
  2024-511990-31-00 5 2022-06-28 Fabry Disease
• A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n … Ended recruitment
  2024-512799-36-00 3 2022-06-16 head and neck squamous cell carcinoma (HNSCC)
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi … Ended recruitment
  2024-513177-48-00 4 2022-06-16 Chronic Hepatitis B Virus Infection
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni … Ended recruitment
  2024-513147-90-00 5 2022-04-26 Primary Immune Thrombocytopenia
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended recruitment
  2023-503517-30-00 5 2022-04-01 Extensive-stage small-cell lung cancer
• Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended recruitment
  2024-516293-29-01 4 2022-03-17 Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla

Showing 409–432 of 653 trials